American Society of Hirudotherapy

Thrombotic antiphospholipid syndrome: From guidelines to clinical management.

Review published in Medicina clinica (2024)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsDrug DevelopmentParedes-Ruiz et al. · Medicina clinica, 2024

Abstract

Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic lupus erythematosus or other systemic autoimmune diseases and the presence of risk factors for cardiovascular disease and bleeding. Anticoagulation with vitamin K antagonists (VKA) remains the cornerstone of therapy for thrombotic APS. As platelets play a central role in APS, low-dose aspirin is the first option for primary thromboprophylaxis in asymptomatic aPL carriers, and also plays a role as combination therapy with VKAs in arterial thrombosis. Treatment with direct oral anticoagulants (DOACs) could be considered in certain low-risk situations, although they are not recommended in patients with arterial thrombosis or triple positive aPL. Adjuvant therapies such as hydroxychloroquine and statins may be useful in complex settings such as thrombotic recurrences or high risk of bleeding. In this article, we review the evidence and the recommendations of the guidelines for the treatment of APS, and provide a critical and practical approach of its management from our clinical perspective.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReviewResearch Support, Non-U.S. Gov't
Indexed MeSH termsAntiphospholipid SyndromeHumansPractice Guidelines as TopicAnticoagulantsThrombosisVenous ThromboembolismAntibodies, AntiphospholipidHydroxymethylglutaryl-CoA Reductase InhibitorsRisk Factors

Summary

Thrombotic manifestations, mainly venous thromboembolism (VTE) and stroke, are the most common and potentially life-threatening presentations of antiphospholipid syndrome (APS). The management of APS requires the assessment of the antiphospholipid antibodies (aPL) profile, of concurrent systemic...

Why This Matters for Hirudotherapy

This review covers thrombotic antiphospholipid syndrome management, discussing anticoagulation with vitamin K antagonists as the cornerstone, with roles for aspirin, direct oral anticoagulants in select cases, and adjuvant therapies like hydroxychloroquine and statins. It is relevant to ASH's domain only in the broad sense of anticoagulant therapeutics—the clinical space shared by hirudin derivatives. The abstract makes no reference to leeches, hirudotherapy, or hirudin-based agents. Its connection to hirudotherapy is indirect and limited.

Citation

Thrombotic antiphospholipid syndrome: From guidelines to clinical management.

Paredes-Ruiz et al. · Medicina clinica, 2024

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.